Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.51 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | BACE1 | P56817 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5106389 | 0.89 | KDM4E (0.53) | KDM4EALDH1A1NPSR1KMT2AL3MBTL1 | |
| SCHEMBL17206120 | 0.88 | HSD17B1 (0.55) | KDM4EALDH1A1NPSR1KMT2AL3MBTL1 | |
| SCHEMBL8471964 | 0.84 | ALDH1A1 (0.52) | KDM4EALDH1A1NPSR1KMT2AL3MBTL1 | |
| SCHEMBL17206122 | 0.81 | HSP90AA1 (0.59) | KDM4EALDH1A1NPSR1KMT2AL3MBTL1 | |
| SCHEMBL5213566 | 0.81 | HSP90AA1 (0.62) | KDM4EALDH1A1NPSR1KMT2AL3MBTL1 | |
| SCHEMBL17205965 | 0.80 | DHODH (0.52) | KDM4EALDH1A1NPSR1KMT2AL3MBTL1 | |
| SCHEMBL28197533 | 0.80 | KDM4E (0.55) | KDM4EALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL9310567 | 0.78 | CHRM3 (0.47) | KDM4EALDH1A1NPSR1KMT2AL3MBTL1 | |
| SCHEMBL13478362 | 0.78 | HDAC1 (0.56) | KDM4EALDH1A1LMNAMAPTGAA | |
| SCHEMBL5213164 | 0.78 | KDM4E (0.59) | KDM4EALDH1A1NPSR1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106232573-B | Method for producing benzidine from aniline by means of ruthenium catalysis | 拜耳作物科学股份公司 | 2020-04-21 | — | — | CN | disclosed |
| EP-3134383-B1 | METHOD FOR PRODUCING BIPHENYLAMINES FROM ANILIDES BY RUTHENIUM CATALYSIS | BAYER CROPSCIENCE AG (DE) | 2020-04-01 | — | — | EP | disclosed |
| US-10246407-B2 | Process for preparing biphenylamines from anilides by ruthenium catalysis | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2019-04-02 | — | — | US | disclosed |
| US-10246407-B2 | Process for preparing biphenylamines from anilides by ruthenium catalysis | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2019-04-02 | — | — | US | disclosed |
| US-10246408-B2 | Process for preparing biphenylamines from anilides by ruthenium catalysis | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2019-04-02 | — | — | US | disclosed |
| US-10246408-B2 | Process for preparing biphenylamines from anilides by ruthenium catalysis | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2019-04-02 | — | — | US | disclosed |
| US-20180362446-A1 | PROCESS FOR PREPARING BIPHENYLAMINES FROM ANILIDES BY RUTHENIUM CATALYSIS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2018-12-20 | — | — | US | disclosed |
| EP-3134383-A1 | METHOD FOR PRODUCING BIPHENYLAMINES FROM ANILIDES BY RUTHENIUM CATALYSIS | Bayer CropScience Aktiengesellschaft (DE) | 2017-03-01 | — | — | EP | disclosed |
| US-20170044094-A1 | PROCESS FOR PREPARING BIPHENYLAMINES FROM ANILIDES BY RUTHENIUM CATALYSIS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2017-02-16 | — | — | US | disclosed |
| US-20170044094-A1 | PROCESS FOR PREPARING BIPHENYLAMINES FROM ANILIDES BY RUTHENIUM CATALYSIS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2017-02-16 | — | — | US | disclosed |
| US-20170044094-A1 | PROCESS FOR PREPARING BIPHENYLAMINES FROM ANILIDES BY RUTHENIUM CATALYSIS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2017-02-16 | — | — | US | disclosed |
| EP-3009420-A1 | Method for the production of biphenylamines from anilides using ruthenium catalysis | Bayer CropScience AG (DE) | 2016-04-20 | — | — | EP | disclosed |
| EP-3009420-A1 | Method for the production of biphenylamines from anilides using ruthenium catalysis | Bayer CropScience AG (DE) | 2016-04-20 | — | — | EP | disclosed |
| WO-2015162144-A1 | METHOD FOR PRODUCING BIPHENYLAMINES FROM ANILIDES BY RUTHENIUM CATALYSIS | BAYER CROPSCIENCE AG (DE) | 2015-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10246407-B2 | Process for preparing biphenylamines from anilides by ruthenium catalysis | SBDS, AGPS, CYP2B6 | KDM4E 565/4885ALDH1A1 392/4885NPSR1 3913/4885 |
| US-10246408-B2 | Process for preparing biphenylamines from anilides by ruthenium catalysis | SBDS, AGPS, CYP2B6 | KDM4E 565/4885ALDH1A1 392/4885NPSR1 3913/4885 |
| US-20170044094-A1 | PROCESS FOR PREPARING BIPHENYLAMINES FROM ANILIDES BY RUTHENIUM CATALYSIS | SBDS, AGPS, CYP2B6 | KDM4E 565/4885ALDH1A1 392/4885NPSR1 3913/4885 |
| US-20180362446-A1 | PROCESS FOR PREPARING BIPHENYLAMINES FROM ANILIDES BY RUTHENIUM CATALYSIS | SBDS, AGPS, CYP2B6 | KDM4E 565/4885ALDH1A1 392/4885NPSR1 3913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.